111 related articles for article (PubMed ID: 15958090)
1. Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis.
Ramsaransing GS; Heersema DJ; De Keyser J
Eur J Neurol; 2005 Jul; 12(7):514-8. PubMed ID: 15958090
[TBL] [Abstract][Full Text] [Related]
2. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis.
Liu B; Shen Y; Xiao K; Tang Y; Cen L; Wei J
Neurol Res; 2012 Mar; 34(2):163-71. PubMed ID: 22333889
[TBL] [Abstract][Full Text] [Related]
3. [The absence of a relation between apolipoprotein E genotypes and the severity of multiple sclerosis in Mexican patients].
Corona T; Guerrero-Camacho JL; Alonso-Vilatela ME; Flores-Rivera Jde J
Rev Neurol; 2010 Jan 1-15; 50(1):19-22. PubMed ID: 20073019
[TBL] [Abstract][Full Text] [Related]
4. Demyelinating lesions in the cervical cord in multiple sclerosis 10 years after onset of the disease. Correlation between MRI parameters and clinical course.
Bonek R; Orlicka K; Maciejek Z
Neurol Neurochir Pol; 2007; 41(3):229-33. PubMed ID: 17629816
[TBL] [Abstract][Full Text] [Related]
5. Apo E in multiple sclerosis and optic neuritis: the apo E-epsilon4 allele is associated with progression of multiple sclerosis.
Pinholt M; Frederiksen JL; Andersen PS; Christiansen M
Mult Scler; 2005 Oct; 11(5):511-5. PubMed ID: 16193886
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
7. Serum NSE level and disability progression in multiple sclerosis.
Koch MW; George S; Wall W; Wee Yong V; Metz LM
J Neurol Sci; 2015 Mar; 350(1-2):46-50. PubMed ID: 25686504
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
[TBL] [Abstract][Full Text] [Related]
9. Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis.
Zakrzewska-Pniewska B; Styczynska M; Podlecka A; Samocka R; Peplonska B; Barcikowska M; Kwiecinski H
Mult Scler; 2004 Jun; 10(3):266-71. PubMed ID: 15222689
[TBL] [Abstract][Full Text] [Related]
10. Serum nicotinamide adenine dinucleotide levels through disease course in multiple sclerosis.
Braidy N; Lim CK; Grant R; Brew BJ; Guillemin GJ
Brain Res; 2013 Nov; 1537():267-72. PubMed ID: 23973746
[TBL] [Abstract][Full Text] [Related]
11. Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis.
Simental-Mendía E; Simental-Mendía LE; Guerrero-Romero F
Neurol Sci; 2017 Sep; 38(9):1665-1669. PubMed ID: 28660563
[TBL] [Abstract][Full Text] [Related]
12. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis.
Booth DR; Arthur AT; Teutsch SM; Bye C; Rubio J; Armati PJ; Pollard JD; Heard RN; Stewart GJ;
J Mol Med (Berl); 2005 Oct; 83(10):822-30. PubMed ID: 16075257
[TBL] [Abstract][Full Text] [Related]
13. [Apolipoprotein E polymorphism as a predictor of progression of multiple sclerosis].
Guerrero AL; Bueno V; Hernández MT; Martín-Serradilla JI; Carrasco E; Cuadrado I
Neurologia; 2003 Apr; 18(3):146-8. PubMed ID: 12677480
[TBL] [Abstract][Full Text] [Related]
14. Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele.
Enzinger C; Ropele S; Strasser-Fuchs S; Kapeller P; Schmidt H; Poltrum B; Schmidt R; Hartung HP; Fazekas F
Arch Neurol; 2003 Jan; 60(1):65-70. PubMed ID: 12533090
[TBL] [Abstract][Full Text] [Related]
15. Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis.
Malhotra S; Fissolo N; Tintoré M; Wing AC; Castilló J; Vidal-Jordana A; Montalban X; Comabella M
J Neuroinflammation; 2015 Mar; 12():48. PubMed ID: 25879961
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E genotype does not influence the progression of multiple sclerosis.
Savettieri G; Andreoli V; Bonavita S; Cittadella R; Caltagirone C; Fazio MC; Girlanda P; Le Pira F; Liguori M; Logroscino G; Lugaresi A; Nocentini U; Reggio A; Salemi G; Serra P; Tedeschi G; Toma L; Trojano M; Valentino P; Quattrone A
J Neurol; 2003 Sep; 250(9):1094-8. PubMed ID: 14504972
[TBL] [Abstract][Full Text] [Related]
17. No effect of APOE and PVRL2 on the clinical outcome of multiple sclerosis.
Ramagopalan SV; Deluca GC; Morrison KM; Herrera BM; Dyment DA; Orton S; Bihoreau MT; Degenhardt A; Pugliatti M; Sadovnick AD; Sotgiu S; Ebers GC
J Neuroimmunol; 2007 May; 186(1-2):156-60. PubMed ID: 17376543
[TBL] [Abstract][Full Text] [Related]
18. Association of apolipoprotein E genotypes with prognosis in multiple sclerosis.
Tamam Y; Tasdemir N; Yalman M; Tamam B
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1122-30. PubMed ID: 22165672
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy.
van der Walt A; Stankovich J; Bahlo M; Taylor BV; van der Mei IA; Foote SJ; Kilpatrick TJ; Rubio JP; Butzkueven H
Neurology; 2009 Sep; 73(13):1018-25. PubMed ID: 19786693
[TBL] [Abstract][Full Text] [Related]
20. Uric acid: a potential biomarker of multiple sclerosis and of its disability.
Moccia M; Lanzillo R; Palladino R; Russo C; Carotenuto A; Massarelli M; Vacca G; Vacchiano V; Nardone A; Triassi M; Morra VB
Clin Chem Lab Med; 2015 Apr; 53(5):753-9. PubMed ID: 25241733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
